Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.

Patients with malignant midgut carcinoid tumours received recombinant interferon-alpha 2a (rIFN-alpha 2a) or rIFN-alpha 2a and chemotherapy (streptozocin and doxorubicin) for 6 months, and then rIFN-alpha 2a alone. Antibodies, mainly of IgG type, binding to rIFN-alpha 2a developed in nine of 22 pati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Rönnblom, L E, Janson, E T, Perers, A, Oberg, K E, Alm, G V
Format: Artigo
Jezik:Inglês
Izdano: 1992
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1554468/
https://ncbi.nlm.nih.gov/pubmed/1516252
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items